Table 2.
Tumor characteristics and treatment, stratified by race/ethnicity
| White (n=401) | Black (n=384) | Hispanic (n=332) | p-value | |
|---|---|---|---|---|
|
| ||||
| Surveillance during year prior to HCC diagnosis | 172 (43.2) | 147 (38.9) | 136 (41.5) | 0.47 |
|
| ||||
| Number of HCC nodules | 0.06 | |||
| One | 212 (52.9) | 186 (48.6) | 177 (53.5) | |
| Two | 70 (17.5) | 49 (12.8) | 48 (14.5) | |
| Three or more | 119 (29.6) | 148 (38.6) | 106 (32.0) | |
|
| ||||
| Maximum tumor diameter (cm) | 5.1 ± 4.1 | 5.8 ± 4.4 | 5.3 ± 4.2 | 0.06 |
|
| ||||
| Distant metastases | 60 (15.0) | 90 (23.4) | 59 (17.8) | 0.008 |
|
| ||||
| Portal vein invasion | 91 (22.9) | 116 (31.0) | 69 (21.2) | 0.005 |
|
| ||||
| HCC within Milan Criteria | 199 (49.6) | 152 (39.6) | 145 (43.7) | 0.02 |
|
| ||||
| BCLC Stage | 0.001 | |||
| Stage 0/A | 185 (46.1) | 149 (38.8) | 129 (39.0) | |
| Stage B | 76 (19.0) | 60 (15.6) | 55 (16.6) | |
| Stage C | 79 (19.7) | 119 (31.0) | 75 (22.7) | |
| Stage D | 61 (15.2) | 56 (14.6) | 72 (21.8) | |
|
| ||||
| Treatment during follow-up | < 0.001 | |||
| Liver Transplantation | 43 (10.7) | 7 (1.8) | 23 (6.9) | |
| Resection | 51 (12.7) | 63 (16.4) | 18 (5.4) | |
| Local ablation | 49 (12.2) | 30 (7.8) | 38 (11.5) | |
| TACE/TARE/SBRT | 115 (28.7) | 83 (21.6) | 102 (30.8) | |
| Systemic therapy | 26 (6.5) | 58 (17.5) | 36 (10.8) | |
| Best supportive care | 117 (29.2) | 134 (34.9) | 115 (34.6) | |
|
| ||||
| Median time to first treatment, days (IQR) | 49 (31 – 79) | 49 (30 – 78) | 47 (29–71.5) | |
BCLC – Barcelona Clinic Liver Cancer; HCC – hepatocellular carcinoma; SBRT – stereotactic body radiation therapy; TACE – transarterial chemoembolization; TARE – transarterial radioembolization
*
Numbers in parentheses represent percentages, except where otherwise specified